<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02412657</url>
  </required_header>
  <id_info>
    <org_study_id>dexaISB</org_study_id>
    <nct_id>NCT02412657</nct_id>
  </id_info>
  <brief_title>Intravenous Dexamethasone to Increase the Analgesic Duration of Interscalene Block</brief_title>
  <official_title>Impact of Two Doses of Intravenous Dexamethasone on the Analgesic Duration of a Single-shot Interscalene Block With Ropivacaine for Shoulder Arthroscopy; a Prospective, Randomized, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maisonneuve-Rosemont Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maisonneuve-Rosemont Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interscalene brachial plexus block provides excellent but time limited analgesia. Intravenous
      dexamethasone increases the analgesic duration of a single-shot interscalene block with
      ropivacaine for shoulder arthroscopic surgery. We want to evaluate the effect of two
      different doses (dexamethasone 10 mg i.v. vs 4 mg i.v. vs placebo) on the analgesic duration
      of a single-shot inter scalene block. Our study hypothesis is that dexamethasone 4 mg i.v. is
      equivalent to dexamethasone10 mg i.v. in prolonging the analgesic duration of a single-shot
      interscalene block with ropivacaine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      75 patients will be randomly assigned to three groups:

        -  D10: dexamethasone 10 mg I.V. diluted in normal saline 20cc, immediately after inter
           scalene block

        -  D4: dexamethasone 4 mg I.V. diluted in normal saline 20cc, immediately after inter
           scalene block

        -  C: control: Normal saline 20cc I.V., immediately after inter scalene block. These
           patient will be recruited from 3 hospitals, with two surgeons performing the surgeries.

      All patients will have their surgery under regional anesthesia only provided by the inter
      scalene plexus block, with ropivacaine 0.5% 20cc.

      In the postoperative period, patients will be given analgesic medication on an as needed
      basis. They will be instructed to take the first analgesic medication once postoperative
      shoulder pain has reached &gt;3/10. They will note the time and day at which this outcome
      occurs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Analgesia</measure>
    <time_frame>48 hours after surgery</time_frame>
    <description>Defined as the time between the performance of the block and the first analgesic request</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Opioid Consumption (mg)</measure>
    <time_frame>48 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scores</measure>
    <time_frame>every 6 hours during the first 48 hours after surgery</time_frame>
    <description>On a 11-points Verbal Numeric Scale 0-10 (0= no pain, 10= worst conceivable pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual Motor Block</measure>
    <time_frame>24 hours and 48 hours</time_frame>
    <description>Scale of 0-2 (0:inability to move fingers, 1: fingers able to move, with diminished strength compared to non operated side, 2: No motor weakness of the fingers)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Disturbance</measure>
    <time_frame>24 hours and 48 hours</time_frame>
    <description>Sleep disturbance scale 0-10 (0: no sleep disturbance from pain, 10: worst conceivable sleep disruption from pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Overall Satisfaction</measure>
    <time_frame>48 hours</time_frame>
    <description>categorical data (1: very satisfied, would recommend this analgesia protocol to others, 0: not satisfied, would not recommend this analgesia protocol to others</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Dexamethasone 10 mg intravenous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexamethasone 10 mg diluted with Normal Saline 17,5 mL i.v. (20 mL total) injected slowly during 30 seconds immediately after performing interscalene brachial plexus block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone 4 mg intravenous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexamethasone 4 mg diluted with Normal Saline 19 mL i.v. (20 mL total) injected slowly during 30 seconds, immediately after performing interscalene brachial plexus block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline 20 mL intravenous</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline 20 mL injected slowly during 30 seconds, immediately after performing interscalene brachial plexus block</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>After the performance of inter scalene plexus blockade, patients will either receive dexamethasone 10 mg i.v. (diluted with 17.5 mL normal saline), dexamethasone 4 mg i.v. (diluted with 19 mL normal saline), or normal saline 20 ml i.v.</description>
    <arm_group_label>Dexamethasone 10 mg intravenous</arm_group_label>
    <arm_group_label>Dexamethasone 4 mg intravenous</arm_group_label>
    <other_name>decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <arm_group_label>Normal Saline 20 mL intravenous</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elective shoulder arthroscopy under ropivacaine single-shot interscalene brachial
             plexus block anesthesia (rotator cuff repair and shoulder decompression)

          -  ASA I-III

          -  Age 18-80 years old

        Exclusion Criteria:

          -  Any contraindication to interscalene brachial plexus block anesthesia

          -  Interscalene brachial plexus block failure

          -  Known local anesthetics allergy

          -  Dexamethasone allergy or intolerance

          -  Any contraindication to acetaminophen

          -  Any contraindication to morphine or hydromorphone

          -  Brachial plexus neuropathies

          -  Chronic pain syndrome other than shoulder pain

          -  Routine use of opioid medication

          -  Routine use of systemic corticosteroid

          -  Pregnancy

          -  Weight below 50 kilograms

          -  Incapability to understand a numeric verbal pain scale

          -  Incapability to consent

          -  Patient refusal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veronique Brulotte, MD MSc FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maisonneuve-Rosemont Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Pierre-Boucher</name>
      <address>
        <city>Longueuil</city>
        <state>Quebec</state>
        <zip>J4M 2A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maisonneuve-Rosemont Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 4M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Hotel-Dieu de Sorel</name>
      <address>
        <city>Sorel</city>
        <state>Quebec</state>
        <zip>J3P 1N5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2015</study_first_submitted>
  <study_first_submitted_qc>April 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2015</study_first_posted>
  <results_first_submitted>March 14, 2016</results_first_submitted>
  <results_first_submitted_qc>March 14, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 12, 2016</results_first_posted>
  <last_update_submitted>October 30, 2016</last_update_submitted>
  <last_update_submitted_qc>October 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maisonneuve-Rosemont Hospital</investigator_affiliation>
    <investigator_full_name>Veronique Brulotte</investigator_full_name>
    <investigator_title>Dre Veronique Brulotte, MD, M.Sc, FRCPC, anesthesiologist</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dexamethasone 10 mg Intravenous</title>
          <description>Dexamethasone 10 mg diluted with Normal Saline 17,5 mL i.v. (20 mL total) injected slowly during 30 seconds immediately after performing interscalene brachial plexus block
Dexamethasone: After the performance of inter scalene plexus blockade, patients will either receive dexamethasone 10 mg i.v. (diluted with 17.5 mL normal saline), dexamethasone 4 mg i.v. (diluted with 19 mL normal saline), or normal saline 20 ml i.v.</description>
        </group>
        <group group_id="P2">
          <title>Dexamethasone 4 mg Intravenous</title>
          <description>Dexamethasone 4 mg diluted with Normal Saline 19 mL i.v. (20 mL total) injected slowly during 30 seconds, immediately after performing interscalene brachial plexus block
Dexamethasone: After the performance of inter scalene plexus blockade, patients will either receive dexamethasone 10 mg i.v. (diluted with 17.5 mL normal saline), dexamethasone 4 mg i.v. (diluted with 19 mL normal saline), or normal saline 20 ml i.v.</description>
        </group>
        <group group_id="P3">
          <title>Normal Saline 20 mL Intravenous</title>
          <description>Normal saline 20 mL injected slowly during 30 seconds, immediately after performing interscalene brachial plexus block
Normal Saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dexamethasone 10 mg Intravenous</title>
          <description>Dexamethasone 10 mg diluted with Normal Saline 17,5 mL i.v. (20 mL total) injected slowly during 30 seconds immediately after performing interscalene brachial plexus block
Dexamethasone: After the performance of inter scalene plexus blockade, patients will either receive dexamethasone 10 mg i.v. (diluted with 17.5 mL normal saline), dexamethasone 4 mg i.v. (diluted with 19 mL normal saline), or normal saline 20 ml i.v.</description>
        </group>
        <group group_id="B2">
          <title>Dexamethasone 4 mg Intravenous</title>
          <description>Dexamethasone 4 mg diluted with Normal Saline 19 mL i.v. (20 mL total) injected slowly during 30 seconds, immediately after performing interscalene brachial plexus block
Dexamethasone: After the performance of inter scalene plexus blockade, patients will either receive dexamethasone 10 mg i.v. (diluted with 17.5 mL normal saline), dexamethasone 4 mg i.v. (diluted with 19 mL normal saline), or normal saline 20 ml i.v.</description>
        </group>
        <group group_id="B3">
          <title>Normal Saline 20 mL Intravenous</title>
          <description>Normal saline 20 mL injected slowly during 30 seconds, immediately after performing interscalene brachial plexus block
Normal Saline</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="22"/>
            <count group_id="B4" value="69"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" lower_limit="44" upper_limit="54"/>
                    <measurement group_id="B2" value="54" lower_limit="50" upper_limit="59"/>
                    <measurement group_id="B3" value="55" lower_limit="51" upper_limit="58"/>
                    <measurement group_id="B4" value="53" lower_limit="33" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Duration of Analgesia</title>
        <description>Defined as the time between the performance of the block and the first analgesic request</description>
        <time_frame>48 hours after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone 10 mg Intravenous</title>
            <description>Dexamethasone 10 mg diluted with Normal Saline 17,5 mL i.v. (20 mL total) injected slowly during 30 seconds immediately after performing interscalene brachial plexus block
Dexamethasone: After the performance of inter scalene plexus blockade, patients will either receive dexamethasone 10 mg i.v. (diluted with 17.5 mL normal saline), dexamethasone 4 mg i.v. (diluted with 19 mL normal saline), or normal saline 20 ml i.v.</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone 4 mg Intravenous</title>
            <description>Dexamethasone 4 mg diluted with Normal Saline 19 mL i.v. (20 mL total) injected slowly during 30 seconds, immediately after performing interscalene brachial plexus block
Dexamethasone: After the performance of inter scalene plexus blockade, patients will either receive dexamethasone 10 mg i.v. (diluted with 17.5 mL normal saline), dexamethasone 4 mg i.v. (diluted with 19 mL normal saline), or normal saline 20 ml i.v.</description>
          </group>
          <group group_id="O3">
            <title>Normal Saline 20 mL Intravenous</title>
            <description>Normal saline 20 mL injected slowly during 30 seconds, immediately after performing interscalene brachial plexus block
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Analgesia</title>
          <description>Defined as the time between the performance of the block and the first analgesic request</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1" lower_limit="11.5" upper_limit="22.8"/>
                    <measurement group_id="O2" value="19.6" lower_limit="16" upper_limit="22.2"/>
                    <measurement group_id="O3" value="11.8" lower_limit="8.7" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Opioid Consumption (mg)</title>
        <time_frame>48 hours after surgery</time_frame>
        <posting_date>12/2017</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores</title>
        <description>On a 11-points Verbal Numeric Scale 0-10 (0= no pain, 10= worst conceivable pain)</description>
        <time_frame>every 6 hours during the first 48 hours after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Residual Motor Block</title>
        <description>Scale of 0-2 (0:inability to move fingers, 1: fingers able to move, with diminished strength compared to non operated side, 2: No motor weakness of the fingers)</description>
        <time_frame>24 hours and 48 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Disturbance</title>
        <description>Sleep disturbance scale 0-10 (0: no sleep disturbance from pain, 10: worst conceivable sleep disruption from pain)</description>
        <time_frame>24 hours and 48 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Overall Satisfaction</title>
        <description>categorical data (1: very satisfied, would recommend this analgesia protocol to others, 0: not satisfied, would not recommend this analgesia protocol to others</description>
        <time_frame>48 hours</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dexamethasone 10 mg Intravenous</title>
          <description>Dexamethasone 10 mg diluted with Normal Saline 17,5 mL i.v. (20 mL total) injected slowly during 30 seconds immediately after performing interscalene brachial plexus block
Dexamethasone: After the performance of inter scalene plexus blockade, patients will either receive dexamethasone 10 mg i.v. (diluted with 17.5 mL normal saline), dexamethasone 4 mg i.v. (diluted with 19 mL normal saline), or normal saline 20 ml i.v.</description>
        </group>
        <group group_id="E2">
          <title>Dexamethasone 4 mg Intravenous</title>
          <description>Dexamethasone 4 mg diluted with Normal Saline 19 mL i.v. (20 mL total) injected slowly during 30 seconds, immediately after performing interscalene brachial plexus block
Dexamethasone: After the performance of inter scalene plexus blockade, patients will either receive dexamethasone 10 mg i.v. (diluted with 17.5 mL normal saline), dexamethasone 4 mg i.v. (diluted with 19 mL normal saline), or normal saline 20 ml i.v.</description>
        </group>
        <group group_id="E3">
          <title>Normal Saline 20 mL Intravenous</title>
          <description>Normal saline 20 mL injected slowly during 30 seconds, immediately after performing interscalene brachial plexus block
Normal Saline</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Veronique Brulotte</name_or_title>
      <organization>MaisonneuveRH</organization>
      <phone>(514)252-3400</phone>
      <email>veronique.brulotte@umontreal.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

